Spago Nanomedical: Q2 ’21: Our comment - Redeye

Redeye comments on Spago Nanomedical's Q2 report, which came without any surprises. We judge the market has lost sight of Spago and that the share could rally to our Base Case upon SpagoPix licensing and Tumorad entering the clinic.

Länk till analysen i sin helhet: https://www.redeye.se/research/819336/spago-nanomedical-q2-21-our-comment?utm_source=finwire&utm_medium=RSS